Related Experiment Video
Updated: Aug 30, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
Selective and Time-Dependent Alterations in Cytochrome P450 (CYP) Enzyme Activity and Expression by Major
Nupur Chaphekar1, Anand Joshi1, Steve Caritis2,3
1Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, USA.
Background And Objective:
The legalization of cannabis in many parts of the USA and worldwide emphasizes the need to study their potential for interaction with drugs. The Cannabis sativa plant contains over 120 phytocannabinoids, with delta-9-tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabinol (CBN) being the most abundant cannabinoids. The aim of this study was to investigate the effect of treatment with individual cannabinoids or mixture of cannabinoids (mix) on the activity and expression of several cytochrome P450 (CYP) enzymes.
Methods:
Primary cultures of human hepatocytes were pretreated with either vehicle or cannabinoids, followed by incubation with a cocktail of CYP substrates. The activity of various CYP enzymes was determined by quantifying the formation of the metabolites of specific CYP substrates using liquid chromatography-tandem mass spectrometry. The messenger RNA (mRNA) expression of various CYP enzymes was determined by quantitative real-time polymerase chain reaction (qrt-PCR).
Results:
A significant (> 2-fold) increase in CYP1A2 activity was observed after chronic exposure to CBN and mix at 3 µM. Similarly, THC and mix treatments at 3 µM led to a significant (> 2-fold) increase in CYP3A4 activity and expression. No major inducive effects were observed on CYP2D6 and CYP2C9. Acute exposure to CBD, CBN, or mix inhibited CYP1A2 activity in a concentration-dependent manner; mix showed mild CYP3A4 inhibition at 3 µM with no major effects on CYP2D6 and CYP2C9 activity.
Conclusions:
These data suggest that cannabinoids selectively alter the activity and expression of CYP enzymes, which may lead to change in exposure of coadministered substrates owing to possible metabolic drug-drug interactions (DDI).
Related Concept Videos
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Chronopharmacokinetics: Time-Dependent Pharmacokinetics
Time-dependent pharmacokinetics refers to non-cyclical changes in drug rate processes over a period of time. It can lead to nonlinear pharmacokinetics, where the relationship between drug concentration and time is not proportional. Non-cyclical...
Pharmacogenetics of Drug Metabolism: Overview
Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

